Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - Reuters
Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRXcwd2ZTOXFZNXBqRlU5ZERTQkVXYW1BZDFpZFpNOXVEdEk1V3pDUEdpa0FadURxcGYtMVNjRHRBSkxoWDdxcWtBcERNVUdaYkU1d1lCWlFMT1dkX3pHOVp1dnUtSko3aERhaDh5UElCd0RlcWpOQmIwNVdHbmJiUWQyZjNOQlY3QUhRWHV1N3h1QnFNdUhVemo2UkltZF9NeklhWjRmNWVuZ2ZfUEJ2Z2dmVnR3Z29N?oc=5" target="_blank">Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say</a> <font color="#6f6f6f">Reuters</font>
Dr Reddy's Laboratories plans to launch its generic semaglutide injection, potentially named Obeda, in India by March 2026, following the patent expiry of semaglutide. The company aims to price it competitively, potentially up to 60% below the branded product.
Dr Reddy's Laboratories has applied to trademark the brand name 'Obeda' for its upcoming generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic. The launch is anticipated in March 2026, coinciding with the patent expiry of semaglutide in India.
Similar Stories
Related coverage based on topic and tags
China's drug regulator accepts Novo Nordisk's application for oral Wegovy - Reuters
China's drug regulator accepts Novo Nordisk's application for oral Wegovy Reuters
August 27, 2026 at 03:47 AMEli Lilly launches oral weight-loss pill Foundayo in UK - Reuters
Eli Lilly launches oral weight-loss pill Foundayo in UK Reuters
August 23, 2026 at 11:07 PMUS FDA approves Lilly's Mounjaro to reduce cardiovascular risk - Reuters
US FDA approves Lilly's Mounjaro to reduce cardiovascular risk Reuters
August 28, 2026 at 06:38 PMUS FDA approves Takeda, Protagonist's drug for rare blood cancer - Reuters
US FDA approves Takeda, Protagonist's drug for rare blood cancer Reuters
August 28, 2026 at 10:16 PMGSK scores regulatory wins for chronic hepatitis B drug, cancer therapy - Reuters
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy Reuters
August 24, 2026 at 07:11 AMMore US employers to drop weight-loss drugs in 2027, as healthcare costs increase - Reuters
More US employers to drop weight-loss drugs in 2027, as healthcare costs increase Reuters
August 25, 2026 at 03:46 PM